Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Benchmark Company","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Sengkang General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by CytoMed Therapeutics

    Menu

    CytoMed Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              CytoMed Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells f...

              Details:

              The collaboration aims to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells to treat cartilage injury, including osteoarthritis of the knee.

              Lead Product(s): Mesenchymal Stem Cell Therapy

              Therapeutic Area: Musculoskeletal Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Sengkang General Hospital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytoMed Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology

              Details:

              This collaboration aims to develop new treatment modalities by using gamma-delta T cells (gdTc) for the treatment of acute myeloid leukemia (AML) and breast cancer patients at an affordable cost.

              Lead Product(s): Gamma Delta T Cell-based Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: MD Anderson Cancer Center

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytoMed Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering

              Details:

              The net proceeds from the initial public offering will be used to advance the clinical development of the Company's CTM-N2D product candidate and to continue technology development of the Company's iPSC-gdNKT product candidate.

              Lead Product(s): CTM-N2D

              Therapeutic Area: Oncology Product Name: CTM-N2D

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Benchmark Company

              Deal Size: $9.6 million Upfront Cash: Undisclosed

              Deal Type: Public Offering April 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY